Brief India: APAC Healthcare Weekly (January 11) – Hengrui, Hansoh, InSilico Medicine, Takeda, Hanmi Pharm and more
In this briefing: APAC Healthcare Weekly (January 11) – Hengrui, Hansoh, InSilico Medicine, Takeda, Hanmi Pharm Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (12 Jan 2025) Aequitas: Shiprocket Limited Pre-IPO Tearsheet Titan’s LGD Move: Expanding Diamond Adoption with BeYon Somany Ceramics: Recovery Building, Normalcy Distant. Maintain ADD 1. APAC Healthcare Weekly (January 11) – Hengrui, Hansoh, InSilico Medicine, Takeda, Hanmi Pharm Jiangsu Hengrui received approval for its innovative drug Retlirafusp alfa Injection in China. Hansoh’s innovative drug Ameile got fifth indication expansion approval in China for NSCLC. InSilico Medicine entered multi-year R&D collaboration valued at $888M with Servier. Takeda Pharmaceutical filed NDA to the FDA seeking approval of rusfertide for the treatment of polycythemia vera. Hanmi Pharmaceutical will distribute and sell Teva’s migraine preventive treatment Ajovy in Korea. Dr. Reddy’s Laboratories has launched Hevaxin vaccine for the prevention of Hepatitis E virus infection in India. 2.